Ever taken medication and felt worse instead of better? You’re not alone—especially if you are a woman.
Women make up half of the population, yet they have historically been excluded from clinical drug trials. Even today, most trials rely on male bodies as the default, overlooking crucial biological differences like hormone cycles, metabolism, and body chemistry. As a result, women are nearly twice as likely to experience adverse drug reactions, making it evident that research treating the male body as the standard risks everyone else’s safety.
These clinical trials don’t just incorporate bad science— they are cemented in gender bias, and they affect the safety of the medicines we rely on.
Why “One Size Fits All” Medicine Fails Women
The roots of this imbalance go deep. In 1977, the U.S. Food and Drug Administration (FDA) recommended excluding women of childbearing age from early-phase clinical trials due to potential pregnancy risks. The policy was so broad that it even precluded women who used contraception, were not sexually active, or whose partners had vasectomies. What began as a precaution quickly turned into near-total exclusion. For over a decade, medical research focused almost exclusively on young, healthy men, treating their bodies as the default.
Even after the policy was reversed in 1993, male-dominant study designs remained the norm. Although women were gradually reintroduced into trials, their results were frequently analysed in aggregate, without considering sex-specific responses, masking crucial biological differences. One of the most common justifications? “Women are hormonally complex, and that distorts the data.” But this overlooks a simple truth:
women are not small men.
Designing around male biology doesn’t simplify science—it limits and distorts it.
A 2001 report by the U.S. Government Accountability Office found that eight out of ten drugs withdrawn from the market posed greater health risks for women. Additionally, the 2020 study in Biology of Sex Differences showed that most preclinical testing still uses male animals and male-derived cells.
One striking example is the sleep aid Ambien. Women metabolised the drug more slowly, leading to next-day drowsiness, impaired driving, and increased accident risk. Despite the drug’s FDA approval in 1992, it wasn’t until 2013 that they cut the recommended dose for women in half.
When Hormones Become an Excuse to Ignore
This imbalance doesn’t remain in academic writing—it affects real lives. Women are more likely to be misdiagnosed, receive incorrect drug dosages, or have their symptoms dismissed altogether. Conditions like heart attacks often go unnoticed in women because their symptoms, such as fatigue or nausea, don’t match the “standard” male presentation taught in medical schools.
Autoimmune diseases, which disproportionately affect women, often take years to be diagnosed. Their pain is frequently attributed to stress, anxiety, or simply described as “overreacting.” This en masse brush-off is no coincidence—it’s what researchers now call medical gaslighting: the dismissal or minimisation of a patient’s bodily knowledge by medical professionals.
From Lab Bench to Prescription: The Gender Gap Persists
The problem also goes beyond the mindset of medical professionals—it’s embedded in our technology. Algorithms used in diagnosis and drug development are often trained on male-biased data, making them less accurate and more dangerous for women. Medical systems aren’t failing women because of their biology. They’re failing because they were never designed with women in mind.
How to Fix a System That Was Never Built for Her
Fixing this gap requires more than just adding women to trials—it demands a systemic redesign. Clinical studies must be built from the ground up with sex-based variables in mind; this means analysing and publishing results by sex, designing protocols that account for hormonal cycles rather than avoiding them, and using both male and female cells and animals in preclinical phases.
Medical journals and regulatory bodies must stop treating sex-disaggregated data as optional. Funding bodies should prioritise studies that address women’s health with the nuance it deserves, not as a side issue, but as central science. Most importantly, researchers must shed the myth of the “neutral” male subject. Science that excludes half the population is not neutral; it’s incomplete.
The purpose of medicine is to heal, but if the science behind it only fits some bodies, then it only serves some people. Women have been treated as biological inconveniences in a system designed around men. How many women have walked away from clinics, not with answers, but with doubt? That’s not just unfair. It’s unsafe.
If we want medicine that truly serves everyone, we must stop asking women to fit the mould and start demanding that the mould itself change.
This is such a powerful and necessary piece. I’m genuinely proud to see important issues like this being voiced so clearly. The way you’ve unpacked how medicine has historically overlooked women isn’t just eye-opening—it’s a call to action. Thank you for shedding light on something that affects so many of us yet is so rarely talked about. More of this, please.